This research on vigabatrin (a.k.a. gamma vinyl GABA, or GVG) was conducted in collaboration with doctors from the New York University (NYU) School of Medicine and the Nathan Kline Institute for Psychiatric Research at a national addiction treatment center in Mexicali, Mexico. The results are published in the February 2005 issue of Synapse, now available online.
"We now have additional clinical data to back up our belief that GVG can be used safely and effectively to treat people suffering from drug addiction," said Brookhaven neuroanatomist Stephen Dewey.
Dewey and Jonathan Brodie, a professor of psychiatry at NYU School of Medicine and this study's lead author, have conducted extensive brain-imaging and behavioral studies on animals at Brookhaven Lab showing that GVG attenuates and in some cases blocks neurological and behavioral changes associated with drug addiction. Last fall, they published results from the first small-scale human clinical trial of GVG for this indication, showing it to be effective in treating cocaine addiction.
"The fact that this drug appears to be effective in treating addiction to both cocaine and methamphetamine is particularly promising, given that methamphetamine abuse is one of the fastest growing drug problems in this country," Brodie said.
These results, especially given the absence of visual side effects in all patients, bring the scientists closer to seeing GVG tested in a larger, placebo-controlled clinical trial in this country.
GVG is approved for the treatment of epilepsy in many countries, including Mexico, but it is not approved for any ind
Contact: Karen McNulty Walsh
DOE/Brookhaven National Laboratory